[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: Iran Unveils 4 New Drugs for Treating Cancer, Diabetes TEHRAN (FNA)- Iranian Vice President for Science and Technology Sorena Sattari attended a ceremony on Tuesday to unveil 4 home-produced drugs for cancer and diabetes treatment. Four Iranian-produced drugs for cancer and diabetes treatment, including Regorafenib and Sorafenib, were unveiled during a ceremony this morning at Eshtehard Industrial Town in Alborz Province. The anti-cancer drugs included the highly important and expensive Regorafenib and Sorafenib, while Empagliflozin and Dapagliflozin were unveiled for the treatment of diabetic patients. Regorafenib, under the trade name chemotherapy drug Stivarga, was first developed by Germany in 2012 for treatment of colorectal cancer, gastrointestinal stromal tumors (GIST), and liver cancer. Iranian researchers managed to obtain the highly complex know-how for the production of this pricey drug after seven years of relentless research and experiment. A 28-tablet pack of Regorafenib costs $5,870 on the global market. The Iranian version is sold at only 5% of the value of the German product. Sorafenib, known by its brand name Nexavar, is used to treat kidney, liver, and thyroid cancer. The product was produced only by Germany and the US until now. The Iranian version of the product is sold at less than one-tenth of its price on the global market, which is as high as $4,880. Empagliflozin, sold under the trade name Jardiance, is used to treat type 2 diabetes. Iran is now the third producer of the medication, after Germany and the US. Dapagliflozin, sold under the brand name Farxiga, is also used to treat type 2 diabetes. Iran managed to obtain the technology to produce the medication after the UK. It is predicted that the two Iranian anti-cancer drugs would potentially generate $1 billion worth of revenues for the country. Iran has taken long strides in producing different types of drugs and medical equipment. Deputy Health Minister for Research and Technology Reza Malekzadeh announced last June that Iranian scientists had produced 22 biological medicine, adding that 97% of the country's needed drugs are manufactured domestically. "Our scientists have succeeded in the production of 22 biological drugs," Malekzadeh said. "Also, the capable pharmacists of our country have been able to produce 97% of the medicine needed by the patients inside the country," he added. Malekzadeh also underlined that cooperation between the Atomic Energy Organization of Iran (AEOI) and the pharmaceutical industry has led the country to approximate independency in the production of different types of radio medicine. Also, the father of Iran's nuclear medicine underlined in February the country's high capabilities in nuclear medicine, and announced production of the most common drug for cancer treatment by Iran. "Technetium is a radio medicine which is taken from molybdenum and is the drug with the highest consumption at the world's nuclear medicine centers," Dr. Mohsen Saqari, a Tehran University professor, told FNA. He added that Iran was able to produce Technetium. "Iran now exports technetium generator (or colloquially a technetium cow or moly cow, a device used to extract the metastable isotope 99mTc of technetium from a source of decaying molybdenum-99) to many countries and if we can produce molybdenum, we will become fully self-sufficient in this area and of course, today we have had many successes in radio medicine production technology," Saqari said. Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||